We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

BVT:JSEBidvest Group Limited Analysis

Data as of 2026-06-28 - not real-time

ZAC 23,814.00

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Bidvest is trading just above its 20‑day SMA (≈23,773) at ZAc 23,814, with a bullish MACD crossover and a neutral RSI near 49, signalling that short‑term momentum remains intact while the market hovers between support at ZAc 22,809 and resistance near ZAc 24,966. Volume is on a downtrend and 30‑day volatility sits at roughly 21%, indicating a more cautious trading environment despite the overall bullish trend.
Fundamentally, the stock appears cheap on a valuation basis – its trailing PE of 13.5 is well below the industry average of 31.5 and the forward PE drops to 10.9, suggesting room for earnings multiple expansion. The dividend yield of 4.16% with a 52% payout ratio is supported by solid operating cash flow (≈ZAc 11.1 bn) and free cash flow (≈ZAc 6.7 bn), though the balance sheet is leveraged (debt‑to‑equity ≈102%). While the DCF fair value (≈ZAc 19,300) is lower than the current price, the “upside/downside” metric points to a modest upside potential, making the stock a borderline overvalued yet income‑attractive play.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price hovering just above 20‑day SMA with bullish MACD
  • Decreasing volume and elevated short‑term volatility
  • Support level provides downside cushion

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Significant valuation headroom vs industry PE
  • Attractive dividend yield with sustainable payout
  • Stable operating cash flow despite high leverage

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Consistent dividend income and modest earnings growth
  • High debt‑to‑equity ratio may limit upside
  • Low beta and diversified business segments provide resilience

Key Metrics & Analysis

Financial Health

Revenue Growth3.70%
Profit Margin4.72%
P/E Ratio13.5
ROE15.38%
ROA6.10%
Debt/Equity102.11
P/B Ratio2.1
Op. Cash FlowZAC11.1B
Free Cash FlowZAC6.7B
Industry P/E31.5

Technical Analysis

TrendBullish
RSI49.4
SupportZAC 22,808.58
ResistanceZAC 24,966.00
MA 20ZAC 23,773.50
MA 50ZAC 23,595.74
MA 200ZAC 23,244.78
MACDBullish
VolumeDecreasing
Fear & Greed Index88.55

Valuation

Fair ValueZAC 19,297.64
Target PriceZAC 29,176.43
Upside/Downside22.52%
GradeFair
TypeBlend
Dividend Yield4.16%

Risk Assessment

Beta0.15
Volatility21.13%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.